Home

ClearPoint Neuro Inc. - Common Stock (CLPT)

14.70
+0.41 (2.87%)
NASDAQ · Last Trade: Apr 26th, 1:34 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close14.29
Open14.34
Bid13.77
Ask15.80
Day's Range14.24 - 15.56
52 Week Range5.105 - 19.22
Volume326,337
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume270,475

Chart

About ClearPoint Neuro Inc. - Common Stock (CLPT)

Clearpoint Neuro Inc is a healthcare technology company focused on transforming the field of neurosurgery through innovative medical devices and advanced imaging solutions. The company develops and commercializes integrated systems that assist neurosurgeons in the precise delivery of therapies to the brain. Their flagship products enhance the surgical process for conditions such as brain tumors and neurological disorders, improving patient outcomes while enabling greater accuracy and efficiency in procedures. Clearpoint Neuro aims to advance the treatment of complex neurological conditions by providing tools that facilitate minimally invasive interventions and enhance the surgeon's capabilities in the operating room. Read More

News & Press Releases

ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025
SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 first quarter on Tuesday, May 13th, after the market close.
Via ACCESS Newswire · April 25, 2025
ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 – Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room
The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025.
Via ACCESS Newswire · April 24, 2025
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · April 17, 2025
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
Achieved Record Revenue for 2024 and Growth of 31%;
Via ACCESS Newswire · February 26, 2025
Earnings Scheduled For February 26, 2025benzinga.com
Via Benzinga · February 26, 2025
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close.
Via ACCESS Newswire · February 14, 2025
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States
Via ACCESSWIRE · November 13, 2024
ClearPoint Neuro Reports Third Quarter 2024 Results
Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million
Via ACCESSWIRE · November 7, 2024
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today
Via ACCESSWIRE · October 31, 2024
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula.
Via ACCESS Newswire · February 12, 2025
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0.
Via ACCESS Newswire · January 27, 2025
Autoliv Posts Strong Sales, Joins United States Cellular, Netflix, Intuitive Surgical And Other Big Stocks Moving Higher On Fridaybenzinga.com
Via Benzinga · October 18, 2024
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · August 27, 2024
CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q2 2024investorplace.com
CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024
ClearPoint Neuro: Q4 Earnings Insightsbenzinga.com
Via Benzinga · March 12, 2024
Earnings Outlook For ClearPoint Neurobenzinga.com
Via Benzinga · March 11, 2024
The 3 Best Brain-Computer Interface Stocks to Buy Nowinvestorplace.com
With the number of U.S. citizens aged 65 and above growing to 55.8 million, we could see brain-computer interface stocks accelerate.
Via InvestorPlace · July 27, 2024
7 Growth Stocks That Could 5X in 5 Yearsinvestorplace.com
These top growth stocks across various sectors have the potential to deliver 5X returns in just five years.
Via InvestorPlace · July 17, 2024
CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q1 2024investorplace.com
CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
7 Penny Stocks That Could Make You a Fortune (If You Dare)investorplace.com
These penny stocks offer robust operational opportunities amid wider economic and market concerns pushing weaker companies downward.
Via InvestorPlace · May 1, 2024
The 3 Most Promising MedTech Stocks to Invest In Nowinvestorplace.com
MedTech stocks are often overlooked despite the inherent healthcare growth trajectory and industry-wide innovative spirit.
Via InvestorPlace · April 11, 2024
Earnings Scheduled For March 12, 2024benzinga.com
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via Benzinga · March 12, 2024
The Top 7 Under-$15 Stocks to Buy in March 2024investorplace.com
These under-$15 stocks to buy are one of the few deals remaining in today's economic environment. Don't miss out.
Via InvestorPlace · March 7, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 29, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · February 28, 2024